4//SEC Filing
Kim Na Yeon 4
Accession 0001683168-20-000014
CIK 0001638287other
Filed
Jan 1, 7:00 PM ET
Accepted
Jan 2, 9:52 PM ET
Size
11.1 KB
Accession
0001683168-20-000014
Insider Transaction Report
Form 4
Kim Na Yeon
Director10% Owner
Transactions
- Award
Common Stock
2019-12-30+1,864,799→ 1,864,799 total(indirect: Held by The E&Healthcare Investment Fund No. 7) - Award
Common Stock
2019-12-30+1,121,190→ 1,121,190 total(indirect: Held by The E&Healthcare Investment Fund No. 6) - Award
Common Stock
2019-12-30+4,335,800→ 4,335,800 total(indirect: Held by The E&Healthcare Investment Fund II)
Footnotes (5)
- [F1]Received in connection with the closing of the merger of GR Merger Sub Inc., a wholly-owned subsidiary of the Issuer, with and into NeuroBo Therapeutics, Inc. (formerly NeuroBo Pharmaceuticals, Inc.) ("NeuroBo") on December 30, 2019 (the "Merger"), in exchange for 3,500,000 shares of common stock issued upon the conversion of Series A preferred stock of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, and 293,019 shares of common stock issued upon conversion of convertible promissory notes of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, held by The E&Healthcare Investment Fund II.
- [F2]Received in connection with the closing of the Merger in exchange for 900,000 shares of common stock issued upon conversion of Series B preferred stock of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, and 80,833 shares of common stock issued upon conversion of convertible promissory notes of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, held by The E&Healthcare Investment Fund No. 6.
- [F3]Received in connection with the closing of the Merger in exchange for 1,500,000 shares of common stock issued upon the conversion of Series B preferred stock of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, and 131,353 shares of common stock issued upon conversion of convertible promissory notes of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, held by The E&Healthcare Investment Fund No. 7.
- [F4]In connection with the closing of the Merger, each share of NeuroBo common stock was exchanged for 1.1431 shares of the Issuer's common stock.
- [F5]Ms. Kim is the Chief Executive Officer of E&I Investment. E&Investment is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and has voting power over the shares held by The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7. Ms. Kim is the Chief Executive Officer of E&Investment, and as such has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein.
Documents
Issuer
NeuroBo Pharmaceuticals, Inc.
CIK 0001638287
Entity typeother
Related Parties
1- filerCIK 0001794779
Filing Metadata
- Form type
- 4
- Filed
- Jan 1, 7:00 PM ET
- Accepted
- Jan 2, 9:52 PM ET
- Size
- 11.1 KB